Skip to main content
SpringerLink
Log in

Targeting Bcl-2 with oblimersen for patients with hormone refractory prostate cancer

  • Topic Paper
  • Published:
World Journal of Urology Aims and scope Submit manuscript

Abstract

Patients with metastatic hormone refractory prostate cancer (HRPC) have limited treatment options and new therapies are needed. Advances in the understanding of the molecular mechanisms implicated in prostate cancer progression have identified many potential therapeutic gene targets including Bcl-2, an important pro-survival regulator of apoptotic cell death. Bcl-2 is overexpressed in a variety of human malignancies including prostate cancer where it has also been associated with androgen independent progression and treatment resistance. Oblimersen is a phosphorothioate antisense oligonucleotide complimentary to the Bcl-2 mRNA and a potent inhibitor of Bcl-2 expression which in pre-clinical testing can significantly enhance the therapeutic effect of chemotherapy, hormone and radiation therapy. Clinical trials evaluating oblimersen in combination with chemotherapy in a variety of cancers have shown good tolerability and promising response rates. Randomized trials are required to determine if oblimersen can enhance the effectiveness of docetaxel in patients with HRPC.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Saad F, Gleason DM, Murray R et al. (2004) Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst 96:879–882

    Google Scholar 

  2. Tannock IF, Osoba D, Stockler MR et al. (1996) Chemotherapy with plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol 14:1756–1764

    Google Scholar 

  3. Kantoff PW, Halabi S, Conaway M et al. (1999) Hydrocortisone with or without in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study. J Clin Oncol 17:2506–2513

    Google Scholar 

  4. Beer TM, Pierce WC, Lowe BA et al. (2001) Phase II study of weekly docetaxel in symptomatic androgen-independent prostate cancer. Ann Oncol 12:1273–1279

    Article  Google Scholar 

  5. Petrylak DP, Tangen CM, Hussain MHA et al. (2004) Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. New Engl J Med 315:1513–1520

    Google Scholar 

  6. Tannock IF, De Wit R, Berry WR et al. (2004) Randomized comparison of weekly or three-weekly docetaxel plus prednisone with mitoxantrone plus prednisone for treatment of patients with advanced hormone-resistant prostate cancer. New Engl J Med 315:1502–1512

    Google Scholar 

  7. Reed JC (1999) Dysregulation of apoptosis in cancer. J Clin Oncol 17:2941–2953

    CAS  PubMed  Google Scholar 

  8. Reed JC (1997) Double identity for proteins of the Bcl-2 family. Nature 387:773–776

    Article  CAS  PubMed  Google Scholar 

  9. Schendel S, Montal M, Reed JC (1998) Bcl-2 family proteins as ion-channels. Cell Death Differ 5:372–380

    Google Scholar 

  10. Jurgensmeier JM, Xie Z, Deveraux Q et al. (1998) Bax directly induces release of cytochrome c from isolated mitochondria. Proc Natl Acad Sci U S A 95:4997–5002

    Google Scholar 

  11. Reed JC (1997) Cytochrome C: can’t live with it; can’t live without it. Cell 91:559–562

    Article  CAS  PubMed  Google Scholar 

  12. McDonnell TJ, Navone NM, Troncoso P et al. (1997) Expression of bcl-2 oncoprotein and p53 protein accumulation in bone marrow metastases of androgen independent prostate cancer. J Urol 157:569–574

    Article  Google Scholar 

  13. Colombel M, Symmans F, Gil S et al. (1993) Detection of the apoptosis-suppressing oncoprotein bc1–2 in hormone-refractory human prostate cancers. Am J Pathol 143:390–400

    Google Scholar 

  14. McDonnell TJ, Troncoso P, Brisbay SM et al. (1992) Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res 52:6940–6944

    Google Scholar 

  15. Raffo AJ, Perlman H, Chen MW, Day ML, Streitman JS, Buttyan R (1995) Overexpression of bcl-2 protects prostate cancer cells from apoptosis in vitro and confers resistance to androgen depletion in vivo. Cancer Res 55:4438–4445

    Google Scholar 

  16. Bubendorf L, Sauter G, Moch H et al. (1996) Prognostic significance of Bcl-2 in clinically localized prostate cancer. Am J Pathol 148:1557–1565

    Google Scholar 

  17. Scherr DS, Vaughan ED JR, Wei J et al. (1999) BCL-2 and p53 expression in clinically localized prostate cancer predicts response to external beam radiotherapy. J Urol 162:12–16

    Google Scholar 

  18. Haldar S, Basu A, Croce CM (1997) Bcl2 is the guardian of microtubule integrity. Cancer Res 57:229–233

    Google Scholar 

  19. Paterson BM, Roberts BE, Kuff EL (1977) Structural gene identification and mapping by DNA-mRNA hybrid-arrested cell-free translation. Proc Natl Acad Sci U S A 74:4370–4374

    Google Scholar 

  20. Zamecnik PC, Stephenson ML (1978) Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide. Proc Natl Acad Sci U S A 75:280–284

    Google Scholar 

  21. Crooke ST (1998) Molecular mechanisms of antisense drugs: RNase H. Antisense Nucleic Acid Drug Develop 8(:133–134

    Google Scholar 

  22. Carpentier AF, Chen L, Maltonti F, Delattre JY (1999) Oligodeoxynucleotides containing CpG motifs can induce rejection of a neuroblastoma in mice. Cancer Res 59:5429–5432

    Google Scholar 

  23. Jansen B, Schlagbauer-Wadl H, Brown BD et al. (1998) bcl-2 antisense therapy chemosensitizes human melanoma in SCID mice. Nat Med 4:232–234

    Google Scholar 

  24. Morris MJ, Tong WP, Cordon-Cardo C et al. (2002) Phase I trial of BCL-2 antisense oligonucleotide (G3139) administered by continuous intravenous infusion in patients with advanced cancer. Clin Cancer Res 8:679–683

    Google Scholar 

  25. Zellweger T, Miyake H, Cooper S et al. (2001) Antitumor activity of antisense clusterin oligonucleotides is improved in vitro and in vivo by incorporation of 2′-O-(2-methoxy)ethyl chemistry. J Pharmacol Exp Ther 298:934–940

    Google Scholar 

  26. Chi KN, Gleave ME, Klasa R et al. (2001) A phase I dose-finding study of combined treatment with an antisense Bcl-2 oligonucleotide (Genasense) and in patients with metastatic hormone-refractory prostate cancer. Clin Cancer Res 7:3920–3927

    Google Scholar 

  27. Tolcher AW, Reyno L, Venner PM et al. (2002) A randomized phase II and pharmacokinetic study of the antisense oligonucleotides ISIS 3521 and ISIS 5132 in patients with hormone-refractory prostate cancer. Clin Cancer Res 8:2530–2535

    Google Scholar 

  28. Waters JS, Webb A, Cunningham D et al. (2000) Phase I clinical and pharmacokinetic study of bcl-2 antisense oligonucleotide therapy in patients with non-Hodgkin’s lymphoma. J Clin Oncol 18:1812–1823

    Google Scholar 

  29. Klasa RJ, Bally MB, Ng R et al. (2000) Eradication of human non-Hodgkin’s lymphoma in SCID mice by BCL-2 antisense oligonucleotides combined with low-dose cyclophosphamide. Clin Cancer Res 6:2492–2500

    Google Scholar 

  30. Lopes De Menezes DE, Hudon N, McIntosh N, Mayer LD (2000) Molecular and pharmacokinetic properties associated with the therapeutics of bcl-2 antisense oligonucleotide G3139 combined with free and liposomal doxorubicin. Clin Cancer Res 6:2891–2902

    Google Scholar 

  31. Tortora G, Caputo R, Damiano V et al. (2001) Combined blockade of protein kinase A and bcl-2 by antisense strategy induces apoptosis and inhibits tumor growth and angiogenesis. Clin Cancer Res 7:2537–2544

    Google Scholar 

  32. Zangemeister-Wittke U, Schenker T, Luedke GH, Stahel RA (1998) Synergistic cytotoxicity of bcl-2 antisense oligodeoxynucleotides and etoposide, doxorubicin and cisplatin on small-cell lung cancer cell lines. Br J Cancer 78:1035–1042

    Google Scholar 

  33. Chi KN, Wallis AE, Lee CH et al. (2000) Effects of Bcl-2 modulation with G3139 antisense oligonucleotide on human breast cancer cells are independent of inherent Bcl-2 protein expression. Breast Cancer Res Treat 63:199–212

    Google Scholar 

  34. Klasa RJ, Gillum AM, Klem RE, Frankel SR (2002) Oblimersen Bcl-2 antisense: facilitating apoptosis in anticancer treatment. Antisense Nucleic Acid Drug Develop 12:193–213

    Google Scholar 

  35. Miyake H, Tolcher A, Gleave ME (1999) Antisense Bcl-2 oligodeoxynucleotides inhibit progression to androgen-independence after castration in the Shionogi tumor model. Cancer Res 59:4030–4034

    Google Scholar 

  36. Miayake H, Tolcher A, Gleave ME (2000) Chemosensitization and delayed androgen-independent recurrence of prostate cancer with the use of antisense Bcl-2 oligodeoxynucleotides. J Natl Cancer Inst 92:34–41

    Google Scholar 

  37. Leung S, Miyake H, Zellweger T, Tolcher A, Gleave ME (2001) Synergistic chemosensitization and inhibition of progression to androgen independence by antisense Bcl-2 oligodeoxynucleotide and paclitaxel in the LNCaP prostate tumor model. Int J Cancer 91:846–850

    Article  Google Scholar 

  38. Tolcher AW, Ropth S, Wynne H et al. (2001) G3139 (Genasense) enhances docetaxel antitumor activity and leads to long-term survivors in the androgen-independent prostate cancer xenograft (PC3) model. AACR-NCI-EORTC Conference on Molecular Targets and Cancer Therapeutics, 2001, abstract 135

  39. De Bono JS, Rowinsky EK, Kuhn J et al. (2001) Phase I Pharmacokinetic (PK) and Pharmacodynamic (PD) Trial of bcl-2 antisense (genasense) and docetaxel (D) in hormone refractory prostate cancer. Proceedings of the American Society of Clinical Oncology, 37th Annual Meeting, 2001, abstract 474

  40. Chi KN, Murray RN, Gleave ME et al. (2003) A phase II study of oblimersen sodium (G3139) and docetaxel (D) in patients (pts) with metastatic hormone-refractory prostate cancer (HRPC). Proceedings of the American Society of Clinical Oncology, 37th Annual Meeting, 2003, abstract 1580

Download references

Author information

Authors and Affiliations

  1. BC Cancer Agency, 600 West 10th Avenue, Vancouver, British Columbia, V5Z 4E6, Canada

    Kim N. Chi

Authors
  1. Kim N. Chi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kim N. Chi.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Chi, K.N. Targeting Bcl-2 with oblimersen for patients with hormone refractory prostate cancer. World J Urol 23, 33–37 (2005). https://doi.org/10.1007/s00345-004-0477-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00345-004-0477-x

Keywords

Search

Navigation